Lopez C H, Bracht A, Yamamoto N S, dos Santos M D
Department of Biochemistry, University of Maringá, Brazil.
Chem Biol Interact. 1998 Nov 6;116(1-2):105-22. doi: 10.1016/s0009-2797(98)00084-2.
The following aspects were investigated in the present work: (a) the action of flufenamic acid on hepatic metabolism (oxygen uptake, glycolysis, gluconeogenesis, uricogenesis and glycogenolysis), (b) the action of flufenamic acid on the cellular adenine nucleotide levels, and (c) the transport and distribution space of flufenamic acid in the liver parenchyma. The experimental system was the isolated perfused rat liver. Perfusion was accomplished in an open, non-recirculating system. The perfusion fluid was Krebs/Henseleit-bicarbonate buffer (pH 7.4), saturated with a mixture of oxygen and carbon dioxide (95:5) by means of a membrane oxygenator and heated to 37 degrees C. The distribution space of flufenamic acid was measured by means of the multiple-indicator dilution technique with constant infusion (step input) of [3H]water plus flufenamic acid. The results of the present work indicate that the metabolic effects of flufenamic acid are the consequence of an uncoupling of oxidative phosphorylation, a conclusion based on the following observations: (a) flufenamic acid increased oxygen uptake, a common property of all uncouplers; (b) the drug also increased glycolysis and glycogenolysis in livers from fed rats (these are expected compensatory phenomena for the decreased mitochondrial ATP formation); (c) flufenamic acid inhibited glucose production from fructose, an energy-dependent process; (d) the cellular ATP levels were decreased by flufenamic acid whereas the AMP levels were increased; and (e) the total adenine nucleotide content was decreased by flufenamic acid and uric acid production was stimulated. Indicator-dilution experiments with flufenamic acid revealed that this substance undergoes flow-limited distribution in the liver and that its apparent distribution space greatly exceeds the aqueous space of the liver. Flufenamic acid changed its behaviour when the portal concentration was increased from 25 to 50 microM. At 25 microM the initial upslope of the outflow profile clearly preceded that of all other concentrations. From the trend of the curves obtained with 50, 100 and 250 microM, one would expect an initial upslope situated at the right of the 50-microM curve. Furthermore, the time of appearance of flufenamic acid in the outflowing perfusate was practically the same irrespective of the portal concentration. For theoretical reasons one would expect progressively longer appearance times when the portal concentration was decreased. It is possible that the amount of flufenamic acid bound to the cell membranes during the early stages of the infusion produced changes that enabled these structures to bind a larger quantity of the drug than originally possible.
(a)氟芬那酸对肝脏代谢(氧摄取、糖酵解、糖异生、尿酸生成和糖原分解)的作用;(b)氟芬那酸对细胞腺嘌呤核苷酸水平的作用;(c)氟芬那酸在肝实质中的转运和分布空间。实验系统为离体灌注大鼠肝脏。灌注在开放的、非循环系统中进行。灌注液为Krebs/Henseleit碳酸氢盐缓冲液(pH 7.4),通过膜式氧合器用氧气和二氧化碳的混合气体(95:5)饱和,并加热至37℃。氟芬那酸的分布空间通过[3H]水加氟芬那酸的恒速输注(阶跃输入)多指示剂稀释技术进行测定。本研究结果表明,氟芬那酸的代谢作用是氧化磷酸化解偶联的结果,这一结论基于以下观察结果:(a)氟芬那酸增加氧摄取,这是所有解偶联剂的共同特性;(b)该药物还增加了喂食大鼠肝脏中的糖酵解和糖原分解(这些是线粒体ATP生成减少的预期代偿现象);(c)氟芬那酸抑制果糖生成葡萄糖,这是一个能量依赖过程;(d)氟芬那酸使细胞ATP水平降低,而AMP水平升高;(e)氟芬那酸使总腺嘌呤核苷酸含量降低,并刺激尿酸生成。氟芬那酸的指示剂稀释实验表明,该物质在肝脏中呈流量限制分布,其表观分布空间大大超过肝脏的水相空间。当门静脉浓度从25μM增加到50μM时,氟芬那酸的行为发生了变化。在25μM时,流出曲线的初始上升斜率明显早于所有其他浓度。从50、100和250μM获得的曲线趋势来看,人们预期初始上升斜率位于50μM曲线的右侧。此外,无论门静脉浓度如何,氟芬那酸在流出灌注液中出现的时间实际上是相同的。出于理论原因,当门静脉浓度降低时,人们预期出现时间会逐渐延长。有可能在输注早期与细胞膜结合的氟芬那酸量产生了变化,使这些结构能够结合比原来更多的药物。